RY 174.38 -0.6382% SHOP 153.13 0.4592% TD 81.72 -0.475% ENB 64.56 -0.6922% BN 84.69 -1.2937% TRI 235.95 1.3226% CNQ 45.8 0.3286% CP 112.58 1.0592% CNR 150.84 1.4733% BMO 144.13 0.2365% BNS 73.95 -0.5246% CSU 4494.0049 1.1951% CM 91.42 0.4947% MFC 43.94 -0.6557% ATD 76.54 0.7105% NGT 60.17 -0.9547% TRP 68.2 0.191% SU 56.95 -0.2627% WCN 257.0 0.1715% L 183.43 1.2698%
Last update at 2025-01-22T19:21:00Z
Microbix Presenting at Florida Capital Event Conference
Fri 17 Nov 23, 12:00 PMMicrobix Clot-Buster Drug Fully-Funded For Return to U.S. Market
Thu 16 Nov 23, 12:00 PMMicrobix & Ulisse Biomed Collaborate on HPV Controls & Assays
Fri 10 Nov 23, 12:00 PMMicrobix QAPs Supporting HPV Testing in Ireland
Fri 27 Oct 23, 11:00 AMMicrobix Presenting at Muskoka Capital Conference
Fri 29 Sep 23, 11:00 AMMicrobix Achieves New QAPs Sales Record
Wed 27 Sep 23, 11:00 AMMicrobix Honours the Passing of its Founder
Wed 13 Sep 23, 08:01 PM| Breakdown | 2022-09-30 | 2021-09-30 | 2020-09-30 | 2019-09-30 | 2018-09-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-09-30 | 2021-09-30 | 2020-09-30 | 2019-09-30 | 2018-09-30 |
| Income before tax | 1.87M | 3.23M | -4.65929M | 0.04M | -8.62157M |
| Minority interest | - | - | - | - | - |
| Net income | 1.79M | 1.63M | -6.22752M | 0.03M | -8.62157M |
| Selling general administrative | 5.00M | 4.22M | 3.54M | 3.74M | 3.61M |
| Selling and marketing expenses | 1.55M | 0.86M | 0.63M | 0.65M | 0.56M |
| Gross profit | 11.12M | 11.04M | 4.66M | 6.55M | 5.37M |
| Reconciled depreciation | 1.04M | 0.82M | 0.69M | 0.57M | 0.69M |
| Ebit | 2.69M | 4.84M | -0.52460M | 1.11M | -7.76954M |
| Ebitda | 3.73M | 5.66M | 0.17M | 1.68M | -7.07946M |
| Depreciation and amortization | 1.04M | 0.82M | 0.69M | 0.57M | 0.69M |
| Non operating income net other | - | - | - | - | - |
| Operating income | 2.69M | 4.84M | -0.52460M | 1.11M | -0.74281M |
| Other operating expenses | 16.47M | 13.76M | 11.05M | 12.30M | 12.40M |
| Interest expense | 0.83M | 1.60M | 1.06M | 1.07M | 0.85M |
| Tax provision | 0.08M | 0.00000M | 1.57M | 0.01M | 0.00000M |
| Interest income | 0.08M | - | - | 0.00000M | 0.00017M |
| Net interest income | -0.74429M | -1.60320M | -1.05610M | -1.06608M | -0.85186M |
| Extraordinary items | - | - | - | - | - |
| Non recurring | - | - | - | - | - |
| Other items | - | - | - | - | - |
| Income tax expense | 0.08M | 1.60M | 1.57M | 0.01M | 0.00000M |
| Total revenue | 19.08M | 18.59M | 10.52M | 13.41M | 12.51M |
| Total operating expenses | 8.51M | 6.21M | 5.19M | 5.44M | 5.26M |
| Cost of revenue | 7.95M | 7.55M | 5.86M | 6.86M | 7.14M |
| Total other income expense net | -0.82656M | -1.60320M | -4.13469M | -1.06608M | -7.87876M |
| Discontinued operations | - | - | - | - | - |
| Net income from continuing ops | 1.79M | 3.23M | -6.22752M | 0.03M | -8.62157M |
| Net income applicable to common shares | 1.79M | 3.23M | -6.22752M | 0.03M | -8.62157M |
| Preferred stock and other adjustments | - | - | - | - | - |
| Breakdown | 2023-09-30 | 2022-09-30 | 2021-09-30 | 2020-09-30 | 2019-09-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-09-30 | 2022-09-30 | 2021-09-30 | 2020-09-30 | 2019-09-30 |
| Total assets | 35.65M | 33.15M | 28.83M | 15.60M | 19.63M |
| Intangible assets | 4.42M | 1.50M | 1.65M | 1.74M | 4.96M |
| Earning assets | - | - | - | - | - |
| Other current assets | - | 0.55M | 0.50M | 0.22M | 0.10M |
| Total liab | 11.03M | 8.21M | 10.27M | 8.98M | 9.09M |
| Total stockholder equity | 24.62M | 24.94M | 18.56M | 6.62M | 10.54M |
| Deferred long term liab | - | - | - | - | - |
| Other current liab | - | 1.83M | 1.79M | 1.49M | 1.46M |
| Common stock | - | 49.92M | 43.61M | 35.36M | 33.91M |
| Capital stock | 49.04M | 49.92M | 43.61M | 35.36M | 33.91M |
| Retained earnings | -36.91141M | -36.87193M | -38.66062M | -41.89401M | -35.66649M |
| Other liab | - | - | - | - | - |
| Good will | - | - | - | - | - |
| Other assets | - | 0.33M | - | 0.00000M | 1.57M |
| Cash | 11.61M | 13.49M | 9.99M | 0.09M | 0.10M |
| Cash and equivalents | - | - | - | - | - |
| Total current liabilities | 4.35M | 2.65M | 5.19M | 4.09M | 4.77M |
| Current deferred revenue | - | 0.55M | 0.74M | 1.32M | 0.64M |
| Net debt | - | -7.66470M | -2.25128M | 6.08M | 6.89M |
| Short term debt | - | 0.27M | 2.66M | 1.29M | 2.66M |
| Short long term debt | 0.11M | 0.11M | 2.45M | 1.13M | 2.58M |
| Short long term debt total | - | 5.82M | 7.74M | 6.17M | 6.99M |
| Other stockholder equity | - | 11.89M | 13.61M | 13.16M | 12.29M |
| Property plant equipment | - | 8.91M | 8.08M | 7.36M | 6.65M |
| Total current assets | 22.30M | 22.41M | 19.09M | 6.49M | 6.45M |
| Long term investments | - | - | - | - | - |
| Net tangible assets | - | 23.44M | 16.90M | 4.88M | 5.58M |
| Short term investments | - | - | - | - | - |
| Net receivables | 4.12M | 3.09M | 4.21M | 1.89M | 1.78M |
| Long term debt | 5.68M | 4.71M | 4.09M | 4.51M | 4.16M |
| Inventory | 5.75M | 5.28M | 4.41M | 4.29M | 4.48M |
| Accounts payable | - | 1.83M | 1.79M | 1.49M | 1.46M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | - | - | - | - |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | - | - | - | -5.90692M | -5.35607M |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | - | - | - | 35.36M | 33.91M |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | - | - | - | - | - |
| Treasury stock | - | - | - | - | - |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | - | 0.33M | - | -0.00000M | -0.00000M |
| Deferred long term asset charges | - | - | - | - | - |
| Non current assets total | 13.35M | 10.74M | 9.73M | 9.11M | 13.18M |
| Capital lease obligations | 0.85M | 1.00M | 1.20M | 0.54M | 0.25M |
| Long term debt total | - | 5.56M | 5.08M | 4.89M | 4.33M |
| Breakdown | 2022-09-30 | 2021-09-30 | 2020-09-30 | 2019-09-30 | 2018-09-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-09-30 | 2021-09-30 | 2020-09-30 | 2019-09-30 | 2018-09-30 |
| Investments | -2.02564M | -0.62234M | -0.81391M | -0.51480M | -1.21800M |
| Change to liabilities | -0.52873M | -0.53054M | 0.56M | -0.57027M | -1.23187M |
| Total cashflows from investing activities | -2.02564M | -0.62234M | -0.81391M | -0.51480M | -1.21800M |
| Net borrowings | -1.38193M | 0.08M | -1.34833M | 0.52M | -1.49699M |
| Total cash from financing activities | 2.06M | 8.41M | 0.80M | 0.52M | 1.74M |
| Change to operating activities | -0.05127M | -0.27498M | -0.12086M | 0.07M | -0.01698M |
| Net income | 1.79M | 3.23M | -6.22752M | 0.03M | -8.62157M |
| Change in cash | 3.50M | 9.89M | -0.00291M | 0.05M | -0.01010M |
| Begin period cash flow | 9.99M | 0.09M | 0.10M | 0.04M | 0.05M |
| End period cash flow | 13.49M | 9.99M | 0.09M | 0.10M | 0.04M |
| Total cash from operating activities | 3.47M | 2.11M | 0.00857M | 0.04M | -0.53700M |
| Issuance of capital stock | 0.00000M | 6.13M | 2.15M | 0.00000M | 3.14M |
| Depreciation | 1.04M | 0.82M | 0.69M | 0.57M | 0.69M |
| Other cashflows from investing activities | 0.00000M | 0.68M | 0.68M | 0.68M | 0.68M |
| Dividends paid | - | - | - | - | - |
| Change to inventory | -0.87741M | -0.11485M | 0.19M | -0.03322M | 0.02M |
| Change to account receivables | 1.12M | -2.29811M | -0.16754M | -0.39599M | 0.02M |
| Sale purchase of stock | 3.44M | 8.33M | 2.15M | 0.00000M | 3.24M |
| Other cashflows from financing activities | 4.52M | 2.82M | -0.65792M | 1.14M | 0.43M |
| Change to netincome | 0.98M | 1.27M | 5.08M | 0.37M | 8.60M |
| Capital expenditures | 2.03M | 1.30M | 0.81M | 0.51M | 1.22M |
| Change receivables | - | - | - | - | - |
| Cash flows other operating | - | - | - | - | - |
| Exchange rate changes | - | - | - | - | - |
| Cash and cash equivalents changes | - | - | - | - | - |
| Change in working capital | -0.34009M | -3.21848M | 0.46M | -0.92871M | -1.20470M |
| Stock based compensation | 0.65M | 0.38M | 0.16M | 0.15M | 0.46M |
| Other non cash items | 0.33M | 0.89M | 3.36M | 0.21M | 8.14M |
| Free cash flow | 1.44M | 0.80M | -0.80534M | -0.47043M | -1.75500M |
Sector: Healthcare Industry: Biotechnology
| Company | Change (CAD) | Price (CAD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| MBX Microbix Biosystems Inc. |
0.05 11.49% | 0.48 | 8.00 | 16.00 | 1.87 | 1.56 | 1.60 | 4.96 |
| FRX Fennec Pharmaceuticals Inc |
- -% | 8.99 | 58.90 | 212.77 | 3.27 | 57.98 | 2.14 | 15.89 |
| MDNA Medicenna Therapeutics Corp |
-0.01 0.72% | 1.38 | - | 204.08 | - | 6.92 | -6.1093 | |
| EPRX Eupraxia Pharmaceuticals Inc |
-0.08 1.74% | 4.51 | - | - | - | 7.62 | -3.8823 | |
| ONC Oncolytics Biotech Inc |
0.07 6.33% | 1.26 | - | - | - | 6.21 | -2.4457 |
Microbix Biosystems Inc., a life science company, develops and commercializes proprietary biological and technological solutions for human health and wellbeing in North America, Europe, and internationally. The company manufactures diagnostic-test products, such as test-controls under the QAPs brand; viral transport medium for collection of patient samples to test for pathogens including virus causing the COVID-19 disease under the DxTM brand; Kinlytic, a biologic thrombolytic drug used to treat blood clots; and antigen products. Microbix Biosystems Inc. was founded in 1988 and is headquartered in Mississauga, Canada.
265 Watline Avenue, Mississauga, ON, Canada, L4Z 1P3
| Name | Title | Year Born |
|---|---|---|
| Mr. Cameron L. Groome | Pres, CEO & Director | NA |
| Mr. James S. Currie | Chief Financial Officer | NA |
| Dr. Kenneth Hughes Ph.D. | Chief Operating Officer | NA |
| Dr. Mark Luscher Ph.D. | Sr. VP of Scientific Affairs | NA |
| Mr. Philip Casselli | Sr. VP of Sales, Bus. Devel. & Marketing | NA |
| Mr. Christopher B. Lobb | Compliance Officer, Gen. Counsel & Sec. | NA |
| Mr. Cameron L. Groome | President, CEO & Director | NA |
| Dr. Mark Luscher Ph.D. | Senior Vice President of Scientific Affairs | NA |
| Mr. Philip Casselli | Senior Vice President of Sales, Business Development & Marketing | NA |
| Mr. Christopher B. Lobb | Compliance Officer, General Counsel & Secretary | NA |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
CA 
AU
UK
US
NZ
Please wait processing your request...